Trodelvy® for the Treatment of Metastatic Urothelial Cancer
The Pharma Data
APRIL 14, 2021
The FDA’s accelerated approval mechanism enables drugs that treat serious diseases with unmet medical need to be approved based on a surrogate or intermediate clinical endpoint. Continued approval is contingent upon verification and description of clinical benefit in a confirmatory trial. About Trodelvy.
52 
Let's personalize your content